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The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal
growth factor receptor (EGFR). The assays largely depend on the acquisition of tumor tissue via biopsy before the initiation of
therapy or after the onset of acquired resistance. However, the limitations of tissue biopsy including tumor heterogeneity and
insufficient tissues for molecular testing are impotent clinical obstacles for mutation analysis and lung cancer treatment. Due to
the invasive procedure of tissue biopsy and the progressive development of drug-resistant EGFR mutations, the effective initial
detection and continuousmonitoring of EGFRmutations are still unmet requirements. Circulating tumor DNA (ctDNA) detection
is a promising biomarker for noninvasive assessment of cancer burden. Recent advancement of sensitive techniques in detecting
EGFR mutations using ctDNA enables a broad range of clinical applications, including early detection of disease, prediction of
treatment responses, and disease progression. This review not only introduces the biology and clinical implementations of ctDNA
but also includes the updating information of recent advancement of techniques for detecting EGFRmutation using ctDNA in lung
cancer.
1. Introduction
Lung cancer is the leading cause of cancer death since
most patients are diagnosed at advanced stage [1, 2]. The
identification of oncogenic driver mutations in lung cancer
has led to the rapid rise of genotype-directed target therapy
such as EGFR tyrosine kinase inhibitors (TKIs) and has
shown dramatic clinical benefits [3]. EGFRmutation analysis
is performed on tumor cells in biopsy or cytology specimens
obtained from bronchoscopy, computed tomography- (CT-)
guided biopsy, surgical resection, or drainage frommalignant
pleural effusions. Sampling tumor tissue other than surgical
resection has inevitable limitations. Tumor heterogeneity in
single snapshot in timemay lead to selection bias. And it may
be difficult to obtain enough DNA for EGFR mutation test if
biopsy tissue lacks tumor cells [4]. Since initial detection and
continuous monitoring of EGFR mutations are needed, the
less invasive procedures are still unmet requirements. Blood-
borne biomarkers such as circulating tumor cells (CTCs)
and circulating tumor DNA (ctDNA) are promising for
the detection of somatic mutations derived from malignant
tumors [5], since they harbor the same genetic lesions as
the primary tumor. Limitation exists on the uncertainty of
collection and diversity of phenotypes from CTCs in blood
[6]. ctDNA genotyping has the potential to be more widely
used than many CTC capture technologies in development
for specific purposes because of important advantages of
ctDNA genotyping over CTCs for specimen processing.
Firstly, CTCs must be separated from the much more abun-
dant hematologic cells in the blood requiring significant
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Figure 1: Source and biology of ctDNA.
laboratory infrastructure to obtain a viable population of
CTCs for study. CTCs in circulation encounter substantial
apoptosis and fragility leading to variability between different
CTC assays. In contrast, most of the ctDNA genotyping
methods require a minimum of special handling and do not
depend on special equipment. Furthermore, ctDNA could be
analyzed togetherwith plasmaDNA fromnormal cells, which
is always present in the circulation. Current technologies are
sensitive enough to detect tumor-specific somatic mutations,
even if the ctDNA fragments represent only a minority of
all DNA fragments in the circulation. In this review, we not
only introduce the biology and clinical implementations of
ctDNA but also include the updating information of recent
advancement of techniques for detecting EGFR mutation
using ctDNA in lung cancer.
2. Source and Biology of ctDNA
2.1. Apoptotic and Necrotic Cells. The finding of circulating
extracellular DNA in the bloodstream was first reported at
1948 [7] and the correlation between cell-free nucleic acid
levels in plasma and cancer was initially researched in 1977
[8]. It was the first study demonstrating that the plasma levels
of circulating free DNA (cfDNA) weremuch higher in cancer
patients than in healthy controls. Tumor cells release small
fragments of cfDNA into circulation bymultiplemechanisms
(Figure 1). The apoptosis and necrosis of cancer cells in the
tumor microenvironment are the main explanations for the
release of the nucleic acids into the blood [3]. The cellular
turnover leads to the increase of apoptotic and necrotic
cells as the tumor increases in volume. The apoptotic and
necrotic cells are engulfed by macrophages and the digested
DNA was released into circulation [9, 10]. When double-
stranded ctDNA in plasma is separated and visualized by
gel electrophoresis, the fragments with a 180 to 1000 bp size
ladder are likely to be formed by apoptosis. In contrast,
DNA released by necrosis is nonspecifically digested and thus
exhibits smears on electrophoretic separation with fragment
sizes about 10,000 bp [10].
2.2. Secretion of Extracellular Vesicles. Cells release differ-
ent types of membrane vesicles of endosomal and plasma
membrane origin called exosomes andmicrovesicles, respec-
tively, into the extracellular environment called extracellular
vesicles (EVs) [11]. EVs play an important role of intercel-
lular communication by serving as vehicles for transferring
cytosolic proteins, lipids, and nucleic acids between cells.
Thus, DNA secreted by EVs has also been suggested as a
potential source of ctDNA. Recent investigations provide
further evidence that EVs carry not only proteins, mRNA,
microRNA, mitochondrial DNA [12], and single-stranded
DNA, but also large fragments (>10 kb) of double-stranded
carrying mutated KRAS, p53 and EGFR sequences [13, 14].
There are many attractive advantages of EV DNA as a
BioMed Research International 3
marker. First, EVs are very stable under different conditions
that they can protect the DNA cargo against degradation
and denaturation in the extracellular environment including
the circulation [15]. Second, EVs can be collected from
complex plasma samples via various isolating methods such
as ultracentrifugation and immunoaffinity isolation based on
specific EV surface markers. Thirdly, EVs can be transported
via circulation and are found in all kinds of cancer associated
body fluids such as pleural effusion, ascites, saliva, and urine
[16]. They provide other sources for ctDNA detection other
than serum.
3. Assays for EGFR Mutations Using ctDNA in
Plasma Samples
Since ctDNA often represents a small fraction (<1.0%) of
total cfDNA, its detection remains challenging [4]. Thus,
direct sequencing approaches like Sanger sequencing or
pyrosequencing are not suitable for detecting EGFR muta-
tions using ctDNA. Several different types of PCR-based
assays have been explored for ctDNA genotyping including
amplification-refractory mutation system (ARMS)/Scorpion
assay, digital PCR, mutant-enriched PCR, peptide nucleic
acid- (PNA-)mediated PCR, PNA-locked nucleic acid (LNA)
PCR clamp, and BEAMing (beads, emulsions, amplification,
and magnetics). In addition to the PCR-based assays, mass
spectrometry genotyping, high-resolution melting (HRM)
analysis, denaturing high performance liquid chromatogra-
phy (DHPLC), next-generation sequencing (NGS), and elec-
tric field-induced release and measurement (EFIRM) were
also extensively developed for detecting EGFR mutations
in various ctDNA containing cancer associated biofluids
including plasma, malignant pleural effusion, and saliva.
Here, we review the technical characteristics of these existing
technologies shortly and compare their sensitivity, specificity,
and predictive value (Table 1).
3.1. ARMS/Scorpion Assay. ARMS, also known as allele-
specific polymerase chain reaction (ASPCR), is a reliable
method for detecting single basemutations or small deletions
which is based on the use of sequence-specific PCR primers
[17]. This allows amplification of only DNA containing target
allele and will not amplify the nontarget allele. Because Taq
DNA polymerase is effective at distinguishing between a
match and a mismatch at the 3󸀠 end of a primer, specific
mutated sequences are selectively amplified. The amplifica-
tion proceeds with full efficiency, when the primer is fully
matched. In contrast, only low-level background amplifica-
tion occurs when the 3󸀠 base is mismatched. Scorpions are
tailed primers containing a PCR primer covalently linked
to a probe. The fluorophore in this probe interacts with a
quencher which also incorporated in the probe and reduces
fluorescence. The fluorophore and quencher become sepa-
rated when the probe binds to the amplicon during PCR that
leads to an increase in fluorescence from the reaction tube
[18]. Specific Scorpion ARMS primers have been designed
and optimized for detecting various EGFR mutations and
have been widely used for ctDNA based assays [19–25].
3.2. Digital PCR. Digital PCR is a refinement of conventional
PCR that can be used to directly quantify and clonally amplify
nucleic acids [26, 27]. It is to amplify a single DNA template
fromminimally diluted samples and generate amplicons that
are exclusively derived from one template. It can be detected
with different fluorophores or sequencing to distinguish
different alleles. Thus, digital PCR transforms the exponen-
tial, analog nature of the conventional PCR into a linear,
digital signal, suitable for statistical analysis. Digital PCR has
been applied in quantification of EGFR mutants in clinical
specimens, providing a promising molecular diagnostic tool
[28].
3.3. Mutant-Enriched PCR. Mutant-enriched PCR is a sensi-
tive assay that can detect one mutant gene among as many
as 103 to 104 copies of the wild-type gene. The sensitivity
is achieved by selective PCR amplification of mutant gene
sequences with a two stage procedure. The first stage entails
the amplification of both mutant and wild-type sequences,
followed by selective digestion of only wild-type sequences
with thermostable restriction enzymes during PCR. A subse-
quent step then amplifies the undigested fragments, enriched
in mutant sequences [29]. This method has been shown to
detect EGFR mutations in various kinds of clinical samples
including pleural fluid and surgically resected tissues from
patients with NSCLC [30–33].
3.4. PNA-Mediated PCR and PNA-LNA PCR Clamp. The
assay uses PNA as both PCR clamp and sensor probe. It is a
synthetic DNA analog inwhich the phosphodiester backbone
is replaced by a peptide-like repeat [34, 35]. Since PNA
contains no charged phosphate groups, the binding between
PNA and DNA is stronger than that between DNA and
DNA. Since PNA/DNA duplexes are more stable than the
relevant DNA-DNA duplexes, PNA will not bind to a not
perfectly matched DNA strand. In addition, PNA oligomers
are not recognized by DNA polymerases and will not be
utilized as primers in subsequence real-time PCR. Thus,
the PNA probe binds tightly to perfectly matched wild-
type DNA templates but not to mismatched mutant DNA
templates and specifically inhibits the PCR amplification of
wild-type alleles without interfering with the amplification of
mutant DNA. A fluorescein tag also allows the PNA probe
to generate unambiguous melting curves for real-time flu-
orescent monitoring [36]. Oligonucleotides containing LNA
hybridize to complementary DNA with an increased affinity
compared to oligonucleotide DNA. Thus, the incorporation
of LNA residues increases the melting temperature of the
oligonucleotide and allows the use of shorter LNA probes
as allele-specific tools in genotyping [37]. In PNA clamp
PCR, amplification of the wild-type sequences is suppressed
and only amplification of the mutant sequences is enhanced.
In combination, LNA probes specifically detect mutant
sequences in the presence of wild-type sequences. Because
PNA clamp primers have wild-type sequences and LNA
probes have mutant sequences, they are located in the same
position. PNA clamp primers competitively inhibit mutant
LNA probes to bind to the wild type, further increasing
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Table 1: Recent advancement of techniques for detecting EGFR mutation using ctDNA in lung cancer.
Study team Sample Oncogenemutation Sample size Method Conclusion
Wang et al. Plasma EGFR 68 (III/IV) ARMS/Scorpionassay
Sensitivity (22.06%), specificity (96.97%),
positive predictive value (88.24%), and negative
predictive value (54.70%) [20]
Liu et al. Plasma EGFR 86 (III/IV) ARMS Sensitivity (67.5%), specificity (100%), andconcordance rate was 84.9% [21].
Goto et al. Plasma EGFR 86 (III/IV) ARMS/Scorpionassay
Sensitivity (43.1%), specificity (100%), positive
predictive value (100%), negative predictive
value (54.7%), and concordance ratio (66.3%)
[22]
Kimura et al. Plasma EGFR 42 (advancedstage)
ARMS/Scorpion
assay
Sensitivity (85.7%), specificity (94.2%), and
concordance ratio (92.9%) [23]
Kimura et al. Plasma EGFR 27 (III/IV) ARMS/Scorpion Detection rate 48.1% [24]
Yung et al. Plasma EGFR 35 (III/IV) Digital PCR Sensitivity (92%) and specificity (100%) [28]
Brevet et al. Plasma EGFR 34 (III/IV) Mass spectrometrygenotyping Detection rate 61% [51]
Hu et al. Plasma EGFR 24(I/II/III/IV)
High-resolution
melting analysis
Positive rate was 100% for patients in stages
II–IV, 81.8% (9/11) for stage I. The sensitivity
was 91.67% and specificity was 100% [52].
Zhao et al. Plasma EGFR 111(I/II/III/IV)
Mutant-enriched
PCR
Concordance ratio (71.2%), sensitivity (35.6%),
and specificity (95.5%). Sensitivity varied
according to the disease stage and pathological
differentiation; early stage (10%) versus
advanced stage (56%). Highly differentiated
(20%) patients and moderately differentiated
(19%) and poorly differentiated subgroup
(77.8%) [31].
Jiang et al. Plasma EGFR 58 (III/IV) Mutant-enrichedPCR
Sensitivity (77.8%), specificity (100%), and
concordance rate (93.1%), more sensitive than
the nonenriched assay [32].
Bai et al. Plasma EGFR 230 (III/IV) DHPLC Sensitivity 81.8% and specificity 89.5% [57]
Kim et al. Plasma EGFR 35 (III/IV) PNA-mediatedPCR
Concordance in the serum and tumor samples
was 17% [42].
Kim et al. Plasma EGFR 57 (III/IV) PNA–LNA PCRclamp
Concordance in the serum and tumor samples
was 87.7% [43].
Xu et al. Plasma EGFR
51 (III/IV)
ARMS/Scorpion
assay Sensitivity (50.0%) Specificity (100%) [25]
Mutant-enriched
PCR Sensitivity (25.0%) Specificity (96.2%)
DHPLC Sensitivity (25.0%) Specificity (92.3%)
60 (III/IV)
Direct sequencing
versus
Mutant-enriched
PCR
Sensitivity 18.3% versus 55.0% [33]
Kuang et al. Plasma EGFR
−T790M 54 (III/IV)
ARMS/Scorpion
assay
Detected in 54% of patients with prior clinical
response to TKI and 29% of prior stable disease
[19]
Taniguchi et al. Plasma EGFR
−T790M 44 (III/IV) BEAMing
82.6% detection rate in patient who developed
PD after EGFR TKI and 43.5% detection rate in
patients were never treated with EGFR TKI
[48]
Sakai et al. Plasma EGFR
−T790M 75 (III/IV)
Mass spectrometry
genotyping
28% detection rate in patient who developed
PD after EGFR TKI [50].
Kukita et al. Plasma EGFR 144 (III/IV)
Next-generation
sequencers: Ion
Torrent PGM
72.7% detection rate in exon 19 deletion, 78.2%
detection rate in L858R or L861Q [66]
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Table 1: Continued.
Study team Sample Oncogenemutation Sample size Method Conclusion
Couraud et al. Plasma
EGFR (exons
18, 19, 20, and
21)
68
(I/II/III/IV)
Next-generation
sequencers: Ion
Torrent PGM
Sensitivity ranged from 55% (EGFR exon 19) to
100% (EGFR exon 18) Considering all
amplicons, the sensitivity was 58% and the
concordance rate was 68% [67].
Wei et al. Saliva EGFR 40 (III/IV) EFIRM Exon 19 Del (AUCs = 0.94, 95% CI, 0.82–1) andL858R (AUCs = 0.96, 95% CI, 0.90–1) [80]
ARMS: amplification-refractory mutation system; DHPLC: denaturing high performance liquid chromatography; PNA: peptide nucleic acid; PNA-LNA:
peptide nucleic acid-locked nucleic acid; BEAMing: beads, emulsions, amplification, and magnetics; NGS: next-generation sequencing; Ion Torrent PGM: Ion
Torrent Personal Genome Machine (PGM) System; EFIRM: electric field-induced release and measurement.
the specificity of detection. In this way, EGFR mutations can
be detected in the presence of 100- to 1,000-fold wild-type
EGFR background [38, 39]. Because of its high sensitivity and
specificity, PNA-LNA PCR clamp was considered suitable
to detect EGFR mutations in histological samples such as
surgical specimens as well as in cytological samples such as
sputum and pleural effusions [40–43].
3.5. BEAMing. BEAMing is a process built on the basis of
four of its principal components-beads, emulsion, amplifi-
cation, and magnetics. BEAMing relies on single-molecule
PCR at a massively parallel scale that millions of individual
DNA molecules can be assessed in this fashion with stan-
dard laboratory equipment, similar to next-generation DNA
sequencing technologies [44, 45]. Briefly, BEAMing starts
with conventional PCR of a predetermined locus and the
PCR product is added to millions of oligonucleotide-coupled
beads in oil. An emulsion is then created that most of the
beads bind only a single DNA molecule followed by the
second round PCR. After the deemulsification and magnetic
capture step, single-base primer extension or hybridization
with mutant-specific probes is performed with different
fluorescent probs. Finally, the detection and quantification
of wild-type or mutant alleles are done by flow cytometry
analysis of the beads. Moreover, specific variants can be
isolated by flow cytometry sorting and used for further
analysis. Because BEAMing analyzes one allele at a time, it is
highly sensitive for the detection of rare mutant allele which
is the exact molecular environment found in ctDNA cases.
It has been shown to be potential for detecting PIK3CA and
EGFR mutations using ctDNA [46–48].
3.6. Mass Spectrometry. In combination with base extension
after PCR, mass spectrometry allows ctDNA detection with
single-base specificity and single DNA molecule sensitivity
[49]. Briefly, DNA is first amplified by PCR and then linear
amplification with base extension reaction which is designed
to anneal to the region upstream of the mutation site. Few
bases are added to the extension primer to produce differ-
ent extension products from wild-type DNA and mutant
DNA. Mass spectrometry has been applied in detection of
EGFR mutations in plasma DNA from lung cancer patients
[50, 51].
3.7. High-Resolution Melting Analysis. HRM analysis is a
powerful technique for the detection of mutations, polymor-
phisms, and epigenetic differences using double-stranded
DNA samples. Typically PCR will be used prior to HRM
analysis to amplify the DNA region in which their mutation
of interest lies.TheHRM process is simply a precise warming
of the amplicon DNA from around 50∘C up to around 95∘C.
When themelting temperature of the amplicon is reached and
the two strands of DNA separate or “melt” apart, the HRM is
to monitor this melting process happening in real time. This
is achieved by using fluorescent dyes that bind specifically
to double-stranded DNA. When the dyes are bound, they
fluoresce brightly and they only fluoresce at a low level in the
absence of double-stranded DNA. The melting temperature
of double-stranded DNA molecules is influenced by several
factors such as the length, GC content, and sequence, which
are properties of the individualmolecule.Thus, the difference
on DNA sequences on various mutants determines the
different melting temperature and will show different HRM
signatures and it was shown to be suitable for serum EGFR
mutation screening for NSCLC patients [52, 53].
3.8. DHPLC. DHPLC uses heteroduplex formation between
wild-type and mutated DNA strands to identify mutations.
Heteroduplex molecules could be separated from homodu-
plex molecules by ion-pair, reverse-phase liquid chromatog-
raphy on a special column matrix with partial heat denatu-
ration of the DNA strands [54]. In EGFR mutation analysis,
mutations in exons 18 to 21 were analyzed using a DNA
endonuclease, SURVEYOR assay, which cleaved mismatched
heteroduplexed DNA [55]. For these analyses DNA could
be prepared from both frozen and formalin-fixed, paraffin-
embedded (FFPE) tumor specimens as well as ctDNA from
plasma [38, 56, 57]. Furthermore, a partially denaturing
HPLC (pDHPLC) assay was developed to detect a large range
of sequence variants with high sensitivity and low detection
limits for minority alleles which could be a useful approach
for routine detection of EGFR variants [58].
3.9. Next-Generation Sequencing (NGS). Over the past years,
there has been a dramatically shift away from automated
Sanger sequencing to the NGS platform for genome analysis
[59]. The NGS technologies include a number of methods
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grouped broadly as template preparation, sequencing and
imaging, and data analysis. The combination of specific
protocols distinguishes one platform from another that deter-
mines the data output from each platform as well as their
quality and cost [60]. In addition to the pure genomic studies,
the NGS technology has also been used to characterize the
evolutionary relationships of ancient genomes, to elucidate
the role of noncoding RNAs in disease, and to detect
oncogenic mutations as well [61–64]. For the oncogenic
detection application, it has been introduced into the clinical
analysis and was further designed as streamlined commercial
products with targeted panels which cover the main genetic
alterations with predictive value, including EGFR mutations
[61, 63–65]. In addition, it has been shown that NGS could
also be used for ctDNA based EGFR mutation analysis [66,
67]. However, the cost is relatively higher than the PCR-based
methods and the clinical usage is still limited.
4. Assays for EGFR Mutations Using ctDNA in
Other Biofluid Samples
There are limited studies of using other noninvasive biofluid
samples for detecting oncogenic mutations in lung cancer
until recent studies using urine and saliva. Although somatic
mutation detection in urine has previously been performed
in patients with cancer, nearly all prior studies were restricted
to patients with genitourinary malignancies [68–70]. Hyman
and colleagues demonstrated that there was 100% concor-
dance between tissue and urinary cfDNA genotype in treat-
ment naı¨ve samples from patients with systemic Histiocytic
disorders using a droplet-digital PCR assay for quantitative
detection of the BRAFV600Emutation [71]. Janku, one of the
colleagues, further implied urinary cfDNAmight have utility
in detecting advanced cancer patients with BRAF-mutant
tumors for treatment response [72].They enrolled 17 patients
with advanced, biopsy-provenBRAF-mutant cancers, includ-
ing melanoma, nonsmall cell lung cancer, and colorectal
cancer. Of these patients, 88% had the same mutation in
urinary cfDNA. Longitudinal analysis further showed that
changes in the amount of BRAF V600E cfDNA correlated
with response to BRAF/MEK targeted therapy. Mutation
detection in urine not only provides convenience for disease
monitoring on an outpatient basis without the need for blood
sampling but also provides flexibility of storage since DNA in
urine can be stabilized for at least 9 days compared to the only
6-hour limit for accurate assessment of cfDNA in plasma [73].
Saliva contains a variety of biomolecules, including DNA,
mRNA, miRNA, protein, metabolites, and microbiota. The
changes in their salivary concentration can be applied to
develop potential biomarkers for detecting early oral and
systemic diseases including oral cancer, lung cancer, and
ovary cancer as well as evaluating disease prognosis and
monitoring the response to treatment [74, 75]. The salivary
genome consists of both human and microbial DNAs. Nearly
70% of the salivary genome is of human origin, while
the remaining 30% is from the oral microbiota [76]. The
quality of salivary DNA is good that 72% to 96% of samples
can be genotyped; 84% can be amplified; and 67% can be
sequenced [77, 78]. In addition, it can be stored for long term
without significant degradation [79]. However, no oncogene
mutatedDNAwas identified in saliva previously. Recently, we
explored the clinical utility of saliva to detect EGFRmutations
in NSCLC patients by developing a core technology, electric
field-induced release and measurement (EFIRM) [80]. We
termed the Saliva-Based EFIRM detection of EGFRmutation
as SABER. The detection of EGFR mutations by SABER
was developed from cell line and validated in lung cancer
xenograph model and clinical sample. And finally, a blinded
test was performed on saliva from 40 late-stage NSCLC
patient saliva samples. The receiver operating characteristic
analysis indicated that EFIRM detected the exon 19 deletion
with an area under the curve (AUC) of 0.94 and the L858R
mutation with an AUC of 0.96.
5. Clinical Implementation of Detecting EGFR
Mutations Using ctDNA in Biofluid
5.1. Concordance with Tissue Biopsy. When ctDNA was used
to detecting EGFR mutations in NSCLC patients, one key
concern was whether or not the genetic variation within
ctDNA was consistent with tumor tissue. Many studies
have demonstrated that blood samples could be used to
reflect genetic changes in tumor of NSCLC patients (Table 1).
Another key issue was what would be the best method for
detecting EGFR mutations using ctDNA. For ctDNA based
EGFR mutation assay, the most commonly used method
is ARMS/Scorpion assay. In average, this method provided
very high specificity but its sensitivity performance varied
largely. Other methods such HRM and Digital PCR seemed
to had better sensitivity [28, 52]. In these studies, due to
different sample cohorts recruited, the results should be
further verified by more comprehensive comparison stud-
ies. Concerning the comparison of the sensitivity of these
methods, recently a meta-analysis study demonstrated that
DHPLC and HRM showed higher sensitivity than ARMS in
subgroup analyses [81]. However, in another report, DHPLC
and mutant-enriched PCR showed lower sensitivity than
ARMS [25]. In addition, another study also emphasized that
different stage and different differentiation of cancer cell may
affect the sensitivity [31]. Thus, more studies are needed to
further clarify this issue.
5.2. Monitoring Drug Resistance. Despite good responses to
EGFR TKIs in the majority of lung cancer patients carrying
sensitive EGFR mutations, most of these patients eventually
become resistant to EGFR TKIs within 1 year [82]. Since
patients at this stage are often too weak to receive second
biopsy, a noninvasive method for detecting T790Mmutation
remains an unmet need for directing patient treatment
strategy. Though T790M mutation was identified at 2005
[83, 84], it is not until 2009 that T790Mmutation was proved
being identified from plasma DNA in 54% (15 of 28) of
patients with prior clinical response to gefitinib/erlotinib,
29% (4 of 14) with prior stable disease, and in 0% (0 of 12)
that had primary progressive disease or were untreated with
gefitinib/erlotinib [19]. In other studies, activating T790M
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mutation was detected in 72.7% and 28% of plasma DNA
using different methods [50, 85]. The progression free sur-
vival of the T790M-positive patients was proved significantly
shorter than that of the T790M-negative patients [50]. How-
ever, unlike the study in using ctDNA to detect EGFR 19Del
or L858R, these studies did not investigate the concordance
with tumor tissue since most of these patients did not receive
second biopsy.
5.3. Early Detection. Surgery is the most effective treatment
for lung cancer but only one-third of lung cancer patients
were diagnosed at early stage and amenable to surgery. Early-
stage detection has the theoretical potential to reduce lung
cancer mortality. Recently, National Lung Screening Trial
(NLST) demonstrated that low-dose computed tomography
screening (LDCT) is an effective way of detecting early lung
cancer and reducing lung cancer mortality [50] compared
to conventional chest X ray image. However, the study also
raised two major unmet needs including the identification
of nonsmoker subjects who carry the highest likelihood of
developing lung cancer and which nodules are likely to be
cancerous before sending patients into surgery. The NLST
eligibility criteria did not clearly identify all the high-risk
subjects for lung cancer who will be most likely to benefit
from LDCT screening and the false positive findings confer
potential harm from unnecessary interventions and undue
anxiety for patients [86, 87]. Recently, using an ultrasensitive
method for quantitating methods, ctDNA was detected in
100% of patients with stage II–IV NSCLC and in 50%
of patients with stage I, with 96% specificity for mutant
allele fractions down to ∼0.02% [88]. Another study also
demonstrated that EGFR DNA can be detected in early-stage
lung cancer ranging from 10% to 81%. However, the appli-
cation of circulating EGFR DNA for lung cancer screening
should be limited on certain high risk groups. According to
the International Cancer Advocacy Network (ICAN) study
(NCT01106781) investigating EGFR gene mutation status in
early-stage Chinese NSCLC patients with adenocarcinoma
(ADC) histology, 55.1% patients were EGFR mutation pos-
itive [89]. The mutation rate is quite similar to the pioneer
study, a prospective, molecular epidemiology study of EGFR
mutations in Asian patients with advanced NSCLC of ade-
nocarcinoma histology [90]. Though the detection of EGFR
DNA in early lung cancer remains rare and the detection
rate is lower than late stage, it remains a promising tool for
screening lung cancer in combination with LDCT in Asian
area.
6. Conclusion
ctDNA and CTC for detecting EGFR mutation have received
more and more interest since a feasible, reliable, and min-
imally invasive approach is needed for clinical research
and practice. ctDNA analysis is likely to be the preferred
option for genotyping, monitoring treatment response, and
early detection with no need to enrich and isolate a rare
population of cells. However, optimizing and standardizing
new technologies with appropriate analytical and clinical
validity remained to be great challenges. In addition, other
biofluids such as saliva and urine also have the potential for
detecting EGFRmutations but large prospective clinical trials
are needed for establishing the clinical utility. Finally, the
combination of LDCT and EGFR mutation detection using
ctDNAmay provide an attractivemethod for screening early-
stage lung cancer which could be the best way to decrease the
high mortality of lung cancer.
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